Inamed Corporation, Inamed Development Company and Bioenterics Corporation v. Lubomyr I. Kuzmak

249 F.3d 1356, 58 U.S.P.Q. 2d (BNA) 1774, 2001 U.S. App. LEXIS 9255, 2001 WL 505969
CourtCourt of Appeals for the Federal Circuit
DecidedMay 15, 2001
Docket00-1292
StatusPublished
Cited by155 cases

This text of 249 F.3d 1356 (Inamed Corporation, Inamed Development Company and Bioenterics Corporation v. Lubomyr I. Kuzmak) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Inamed Corporation, Inamed Development Company and Bioenterics Corporation v. Lubomyr I. Kuzmak, 249 F.3d 1356, 58 U.S.P.Q. 2d (BNA) 1774, 2001 U.S. App. LEXIS 9255, 2001 WL 505969 (Fed. Cir. 2001).

Opinion

CLEVENGER, Circuit Judge.

Inamed Corp., Inamed Development Co., and BioEnterics Corp. (collectively, “Inamed” or “appellants”) appeal from an order of the United States District Court for the Central District of California dismissing their action for declaratory judgment against defendant Lubomyr I. Kuzmak, M.D., for lack of personal jurisdiction. Inamed Corp. v. Kuzmak, No. 99-2160 (C.D.Cal. Feb. 24, 2000) (“Inamed Corp.”). Because we conclude that the district court erred in determining that it lacked personal jurisdiction over the defendant, we reverse and remand.

I

This appeal stems from a declaratory judgment action related to four patents directed to devices and methods for the surgical treatment of obesity. The defendant-appellee, Dr. Kuzmak, is listed as a co-inventor of U.S. Patent No. 4,592,339 (“the '339 patent”), directed to an adjustable silicone gastric band used to constrict the size of a stomach, and U.S. Patent No. 4,696,288 (“the '288 patent”), directed to a method for performing gastric banding surgery using a calibrating tube and electronic sensor apparatus. Dr. Kuzmak is also listed as sole inventor of U.S. Patent No. 5,074,868 (“the '868 patent”), directed to a reversible gastric band, and U.S. Pat *1359 ent No. 5,226,429 (“the '429 patent”), directed to a method for performing a gastric banding operation via laparoscopic surgery. At all times relevant to this appeal, Dr. Kuzmak has been a resident of New Jersey. The appellants are all corporations with principal places of business in California.

Between 1989 and 1993, Inamed entered into four license agreements with Dr. Kuz-mak involving his four patents. The fourth agreement, dated July 1, 1993 (“the 1993 Agreement”), superseded the three previous agreements between Dr. Kuzmak and Inamed. The 1993 Agreement granted Inamed an exclusive license to practice all four patents in exchange for royalty fees based on Inamed’s commercial exploitation of the patents. From 1992 to 1998, Inamed made annual royalty payments to Dr. Kuzmak of more than $1.3 million based on the sale of gastric bands manufactured in California by Inamed. In 1998, Inamed attempted to renegotiate the license agreement. When these negotiations proved unsuccessful, Inamed terminated the contract on December 6, 1998.

Following the contract’s termination, Dr. Kuzmak sent a letter to Inamed, dated December 21, 1998, containing the following language concerning three of the four patents:

For the record, we should note that we do not concede that the '339 patent is invalid and would, in fact, contend that [Inamed] infringes valid claims of the '339 patent.
Regarding the '429 patent, [Inamed] is clearly a willful infringer of this patent.
It also appears from what we have seen that [Inamed] induces infringement of the '288 patent and thus that [Inamed] is currently a willful infringer of the '288 patent as well.

On February 26, 1999, Inamed commenced a declaratory judgment action against Dr. Kuzmak in California, seeking a declaration of patent invalidity, unen-forceability, and noninfringement. In-amed also alleged patent misuse and breach of contract. On April 5, 1999, Dr. Kuzmak filed a motion to dismiss for lack of personal jurisdiction. The district court subsequently found that Dr. Kuzmak’s contacts with California were not sufficient to support the exercise of either general or specific jurisdiction over him, and thus dismissed the action. Instrumental to the district court’s determination were the factual findings that Dr. Kuzmak’s license agreements with Inamed had already been terminated, and that Dr. Kuzmak conducted all discussions concerning these agreements via telephone and mail from New Jersey. Inamed Corp., slip. op. at 10. Inamed now appeals.

II

Whether a court has personal jurisdiction over a defendant is a question of law which we review de novo. Dainippon Screen Mfg. Co. v. CFMT, Inc., 142 F.3d 1266, 1269, 46 USPQ2d 1616, 1619 (Fed.Cir.1998). Moreover, we apply the law of the Federal Circuit, rather than that of the regional circuit in which the case arose, when we determine whether a district court properly declined jurisdiction, because the jurisdictional question at issue here is “intimately involved with the substance of the patent laws.” Akro Corp. v. Luker, 45 F.3d 1541, 1543, 33 USPQ2d 1505, 1506 (Fed.Cir.1995).

Determining whether personal jurisdiction exists over an out-of-state defendant involves two inquiries: whether a forum state’s long-arm statute permits service of process, and whether the assertion of personal jurisdiction would violate due process. Genetic Implant Sys., Inc. v. *1360 Core-Vent Corp., 123 F.3d 1455, 1458, 43 USPQ2d 1786, 1788 (Fed.Cir.1997) (citing Burger King Corp. v. Rudzewicz, 471 U.S. 462, 471-76, 105 S.Ct. 2174, 85 L.Ed.2d 528 (1985)). However, because California’s long-arm statute is coextensive with the limits of due process, the two inquiries collapse into a single inquiry: whether jurisdiction comports with due process. Dainippon, 142 F.3d at 1270, 46 USPQ2d at 1619-20; see also Cal.Civ.Proc.Code § 410.10 (Deering 2001); Panavision Int’l, L.P. v. Toeppen, 141 F.3d 1316, 1320, 46 USPQ2d 1511, 1514 (9th Cir.1998).

In the seminal case on personal jurisdiction, International Shoe Co. v. Washington, 326 U.S. 310, 66 S.Ct. 154, 90 L.Ed. 95 (1945), the Supreme Court held that “due process requires only that in order to subject a defendant to a judgment in personam, if he be not present within the territory of the forum, he have certain minimum contacts with it such that the maintenance of the suit does not offend ‘traditional notions of fair play and substantial justice.’ Id. at 316, 66 S.Ct. 154 (emphasis added). The first “minimum contacts” prong of the due process inquiry focuses on whether the defendant “has purposefully directed his activities at residents of the forum and the litigation results from alleged injuries that arise out of or relate to those activities.” Burger King, 471 U.S. at 471-76, 105 S.Ct. 2174. The second prong of “fair play and substantial justice” gives the defendant an opportunity to “present a compelling ease that the presence of some other considerations would render jurisdiction unreasonable.” Id. at 476-77, 105 S.Ct. 2174.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
249 F.3d 1356, 58 U.S.P.Q. 2d (BNA) 1774, 2001 U.S. App. LEXIS 9255, 2001 WL 505969, Counsel Stack Legal Research, https://law.counselstack.com/opinion/inamed-corporation-inamed-development-company-and-bioenterics-corporation-cafc-2001.